middle.news
Nova Eye Medical Posts 26% Sales Growth and Positive H2 EBITDA
11:03am on Wednesday 29th of July, 2026 AEST
•
Healthcare
Read Story
Nova Eye Medical Posts 26% Sales Growth and Positive H2 EBITDA
11:03am on Wednesday 29th of July, 2026 AEST
Key Points
26% annual sales growth to US$23.7 million
Positive EBITDA of US$0.14 million in H2 FY26
Sales excluding China up 29%, surpassing guidance
FY27 sales guidance US$26-31 million excluding China
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nova Eye Medical (ASX:EYE)
OPEN ARTICLE